DanielOntanedaMDPhD

PubMed

• Disparities in Utilization of Outpatient Telemedicine for Neurologic Care.
  Marisa Patryce McGinley, Tucker Harvey, Daniel Ontaneda, Allison L Weathers, Bryan R Cobb
  Neurology. Clinical Practice. 2025-02-01
• Breaking Barriers in Multiple Sclerosis.
  Daniel Ontaneda, Veronique E Miron
  Multiple Sclerosis. 2024-12-01
• Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis.
  Lorraine V Kalia, Angelica Asis, Nathalie Arbour, Amit Bar-Or, Riley Bove
  Nature Reviews. Neurology. 2024-12-01

Journal Articles

• Keep the Worms in the Mud  
  Daniel Ontaneda, MD, JAMA Neurology
• Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives  
  Ontaneda D, Fox RJ, Chataway J, Lancet Neurology, 1/1/2015
• Experience with Fingolimod in clinical practice  
  Hersh C, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, Ontaneda D, Int J Neurosci, 1/29/2014
• Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study  
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe MJ, Phillips MD, Fox RJ, Journal of Neuroimaging, 1/1/2014
• Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?  
  Ontaneda D, Fox RJ, Int J Neurosci, 1/1/2014
• Diffusion Tensor Imaging before, during and after progressive multifocal leukoencephalopathy  
  Ontaneda D, Sakaie K, Lin J, Lowe MJ, Phillips MD, Fox RJ, European Journal of Neurology, 1/1/2014
• Sensitivity to Volatile Anesthetics in Patients with Dementia: A Case-control Analysis  
  Perez S, Guebe M, Ontaneda D, Dalton J, Kurz A, Sessler D, Canadian Journal of Anesthesia, 1/1/2014
• Risk Stratification and mitigation in multiple sclerosis  
  Ontaneda D, Cohn S, Fox, R, Multiple Sclerosis and Related Disorders Mult Scler Relat Disord, 1/1/2014
• Multiple sclerosis treatment: risk mitigation  
  Ontaneda D, Fox RJ, Continuum (Minneap Minn), 1/1/2013
• The benefits and risks of alemtuzumab in multiple sclerosis  
  Ontaneda D, Cohen JA, Expert Rev Clin Pharmacol, 1/1/2013
• Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures  
  Ontaneda D, Larocca N, Coetzee T, Rudick R, On behalf of the NMSS MSFC Task Force listed in Appendix, Mult Scler J, 1/1/2012
• Benefits versus risks of latest therapies in multiple sclerosis: a perspective review  
  Ontaneda D, Di Capua D, Therapeutic Advances in Drug Safety, 1/1/2012
• Early tolerability and safety of fingolimod in clinical practice  
  Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen J, Bermel R, J Neurol Sci, 1/1/2012
• EDSS Improvement: Recovery of Function or Noise?  
  Ontaneda D, Cohen JA, Mult Scler J, 1/1/2012
• Relapsing-Remitting Multiple Sclerosis -Current Treatment Options and Perspectives for the Future  
  Ontaneda Daniel, Rae-Grant Alex, European Neurological Review, 1/1/2010
• Race/ethnic differences in AD survival in us Alzheimer's disease centers (Author reply)  
  Ontaneda D, Neurology, 1/1/2009
• Join now to see all

Books/Book Chapters

• Multiple Sclerosis: A Guide to Pharmacologic Treatment. 
  Ontaneda DSEEd edizioni scientifiche, Turin, Italy2013
• The 5 Minute Neurology Consult. 
  Chapter: Neuromyelitis Optica. 
  Ontaneda D, Rae-Grant AD Neuromyelitis OpticaEditors: Lyne DJ, Newton HB, Rae-Grant AD.Lippincott Williams & Wilkins, Philadelphia, PAEdition 2nd,
• Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation. 
  Chapter: Emerging Therapies in MS. 
  Ontaneda D, Fox REditors: Rae-Grant AD, Fox RJ, Bethoux F.Demos Medical Publishing

Abstracts/Posters

• Vitamin D levels are associated with low cortical thickness in secondary progressive MS.
  Ontaneda D, Planchon S, Cohen J, Fisher E, Americas/European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Boston, MA, 1/1/2014
• Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in multiple sclerosis.
  Cohn S, Bermel R, Hara C, Hersh C, Fox RJ, Cohen J, Ontaneda D, Americas/European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Boston, MA, 1/1/2014
• Pilot clinical trial of vitamin d supplementation in secondary progressive multiple sclerosis.
  Ontaneda D, Cohen JA, Clinical and Translational Science 2014, Translational Science 2013 Meeting, Washington, DC, 1/1/2014
• Early tolerability of dimethyl fumarate for treatment of multiple sclerosis.
  Cohn S, Bermel R, Fox R, Cohen J, Ontaneda D, American Academy of Neurology Annual Meeting, Philadelphia, PA, 1/1/2014
• Region of interest versus tractography analysis of the corticospinal tract using diffusion tensor imaging (P112).
  Ontaneda D, Atthe B, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, Clinical and Translational Science, Translational Science 2013 Meeting, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Washington, DC, 2013; Copenhagen, Denmark, 2013, 1/1/2013
• Tolerability and Efficacy of Fingolimod in Clinical Practice (P01.183).
  Hersh C, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, Ontaneda D, Neurology, American Academy of Neurology Annual Meeting, San Diego, CA, 1/1/2013
• Cardiovascular Effects and Safety of Fingolimod in Clinical Practice (P04.138).
  Ontaneda D, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, Neurology, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Diffusion tensor imaging predicts development of natalizumab-associated progressive multifocal leukoencephalopathy (1422).
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Lyon, France, 1/1/2012
• Four-year evolution of multiple sclerosis lesions using diffusion tensor imaging (1419).
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Lyon, France, 1/1/2012
• Four-Year Evolution of Brain Tissue Integrity Using Diffusion Tensor Imaging in Multiple Sclerosis (P03.037).
  Ontaneda D, Sakaie K, Lin J, Wang X, Lowe M, Phillips M, Fox R, Neurology, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Early Tolerability and Safety of Fingolimod in Clinical Practice (P04.130).
  Ontaneda D, Hara-Cleaver C, Rudick R, Cohen J, Bermel R, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Depression and disease-modifying agents in multiple sclerosis: a propensity matched comparison (P709).
  Ontaneda D, Cohen JA, European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, Amsterdam, The Netherlands, 1/1/2011
• Anatomical Specificity of Diffusion Tensor Imaging and The Timed 25 Foot Walk (S46).
  Ontaneda D, Sakaie K, Lin J, Wang, X, Lowe MJ, Phillips MD, Fox RJ, Int J MS Care, Consortium of Multiple Sclerosis Centers Annual Meeting, Montreal, Canada, 1/1/2011
• Identifying the Start of Multiple Sclerosis Inflammation: A Serial DTI Study (IN7-2.010).
  Ontaneda D, Sakaie K, Lin J, Wang, X, Lowe MJ, Phillips MD, Fox RJ, American Academy of Neurology Annual Meeting, Toronto, Canada, 1/1/2010
• Is NMO a Paraneoplastic Marker?
  Ontaneda D, Saupe W, Fox RJ, American Academy of Neurology Annual Meeting, Toronto, Canada, 1/1/2010
• Cryptococcosis of the CNS Presenting with Disseminated White Matter Lesions.
  Ontaneda D, Shook, S, American Society of Neuroimaging Meeting, San Francisco, CA, 1/1/2010
• Transient locked in syndrome and basilar occlusion (P07).
  Ontaneda D, Shook, S, Journal of Neuroimaging, American Society of Neuroimaging Meeting, Orlando, FL, 1/1/2009
• Hand muscle atrophy in multiple sclerosis (P08).
  Ontaneda D, Shook, S, Journal of Neuroimaging, American Society of Neuroimaging Meeting, Tucson, AZ, 1/1/2008
• Factors related to the absence or discontinuation of disease modifying therapy in an Academic MS Center (S59).
  Ontaneda D, Ordonez L, Skromne E, Hutton G, Rivera V, Int J MS Care; Consortium of Multiple Sclerosis Centers Annual Meeting, Scottsdale, AZ, 1/1/2006
• Join now to see all

Lectures

• Where Are We With Vitamin D, and What's All the Fuss? 
  Cleveland, OH - 1/27/2014
• Advances in secondary progressive multiple sclerosis. 
  Monterrey, Mexico - 1/19/2014
• Current and Future Therapies in Multiple Sclerosis. 
  Washington, DC - 1/1/2014
• Risk of Therapies in Multiple Sclerosis. 
  Washington, DC - 1/1/2014
• Mellen Center Update on Multiple Sclerosis (MS) 
  Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Cleveland, Ohio - 6/21/2013
• Clinicians rate risk of disabling MS less than risk of effective treatment. 
  Vienna, Austria - 1/23/2013
• Multiple Sclerosis Treatment: from conventional immunomodulatory drugs to new imunossupressive drugs, and patients risk management. 
  Sao Paulo, Brazil - 1/23/2013
• Risk Stratification in Using Disease Modifying Therapy in 2013. 
  Cleveland, OH - 1/21/2013
• Update on Multiple Sclerosis. 
  Villahermosa, Mexico - 1/14/2013
• Treatment of Stoke Complications. 
  Villahermosa, Mexico - 1/13/2013
• What Does Progressive MS Mean? What's Hot in MS Program. 
  Cleveland, OH - 1/3/2012
• An Update on Oral Therapies in Multiple Sclerosis. 
  1/2/2012
• Identifying the Start of the Multiple Sclerosis Lesion: A review of Pre-lesional Data. 
  1/28/2010
• Cheer-leading Swinging and Swimming Interrupted. 
  1/15/2009
• A Toddler with Twitches. 
  1/7/2007
• Join now to see all